COGNITIVE-SYSTEMS
4.5.2022 13:52:11 CEST | Business Wire | Press release
Cognitive Systems Corp. announced today the launch of Caregiver Aware, a revolutionary advancement in preventative health. Working directly with service providers during development to understand their challenges, Caregiver Aware was designed with flexible go-to-market options that leverage providers’ existing infrastructure and hardware. Building on the success of its Home Aware security product that commercially launched in 2019, Caregiver Aware’s predictive analytics has the potential to significantly disrupt the broadband services market and our definition of “smart home.”
Caregiver Aware is powered by WiFi Motion ™, which is currently active in over 70 countries and leverages connected IoT devices to transform the entire home into a motion-sensing network without additional hardware. It is an end-to-end solution featuring Cognitive Systems' patented algorithms, clean iOS and Android app interfaces. Backed by robust integration support from Cognitive’s QA and commercialization experts, the optimized data management system does not impact broadband performance. This launch represents a key moment for service providers looking to enter the rapidly growing field of remote eldercare by providing their customers with a tool for aging in place.
“Technology is accelerating the shift from reactive to proactive healthcare and we want to help lead that charge,” said Taj Manku, co-founder and CEO of Cognitive Systems. “Caregiver Aware has been on our product roadmap from the start, but the pandemic has made us all acutely aware of the need for innovation in preventative health. Our goal with this product is to create a bridge for service providers to build a care-focused ecosystem using data analytics, which will be a game-changing step in shaping future broadband services.”
Caregiver Aware is currently being trialed with service provider partners. It allows caregivers to complete remote wellness checks and view live motion in a loved one's home without intruding on their privacy or independence in the way cameras or wearable devices do. This launch represents the tip of the iceberg for remote eldercare monitoring, with new features already in development aimed at capturing behavioural patterns based on natural motion AI, improving localization and enabling customized notifications.
“As we worked towards a full-scale launch with more advanced features, user feedback confirmed immediate value in providing people with the peace of mind knowing a loved one is home, safe and active,” says Amanda Forsyth, Director of Product Management at Cognitive Systems. “This first iteration of Caregiver Aware is an important steppingstone towards a proactive health model and, with the majority of adults wanting to age in place, Caregiver Aware not only fills an industry need but a societal one.”
With aging populations around the world, the remote eldercare industry is poised to take off. However, with current world events and chip shortages, integration timelines can be lengthy. Service providers looking to enter the market need to start conversations now about where care solutions fit into their product roadmaps.
Learn more about how WiFi Sensing is ushering in a new era of preventative healthcare here .
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005187/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom